A case with primary signet ring cell adenocarcinoma of the prostate and review of the literature

Çelik, Orçun; Budak, Salih; Ekin, Gökhan; Akarken, İlker; İlbey, Yusuf Özlem

doi:10.4081/aiua.2014.2.148

Cited by 11 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, patients with advanced prostate cancer had a main complaint of acute urinary retention and underwent palliative TUR-P. Of the patients included in our study, the 15 patients who underwent hormone therapy and radiotherapy presented the highest survival rate of 36 months. Overall, based on the treatment characteristics of included studies 3 4 9 10 42 43 44 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 and patients, aggressive and comprehensive treatment should be considered, which likely will rely on early invasive surgery combined with hormone treatment and adjuvant radiation therapy.…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical analysis of PD-L1 and tumor-infiltrating immune cells expression in the tumor microenvironment of primary signet ring cell carcinoma of the prostate

Fan¹,

Liu²,

Teng³

et al. 2022

Asian Journal of Andrology

View full text Add to dashboard Cite

Primary signet ring cell carcinoma (SRCC) of the prostate is a rare neoplasm. However, its potential tumorigenic mechanism, clinicopathological features, and prognostic outcome have not been systematically described. To determine the pathogenic mechanism, we detected distributions of programmed cell death-ligand 1 (PD-L1), programmed death 1 (PD-1), and cellular components in the tumor microenvironment, including tumor-infiltrating lymphocytes (CD4 and CD8), tumor-associated macrophages (TAMs; CD163 and CD68), and tumor-associated fibroblasts (vimentin and alpha-smooth muscle actin [α-SMA]), in tumor tissues from four patients with primary prostatic SRCC compared with corresponding adjacent tissues and tumor tissues from 30 patients with prostate adenocarcinoma (PCa) by immunohistochemical staining. We found higher expression of PD-L1, CD163, and CD68 in primary SRCC specimens than that in both corresponding adjacent nontumor specimens and PCa specimens with different Gleason scores, indicating that TAMs may participate in the malignant biological behavior of primary SRCC of the prostate. For further analysis, we searched electronic journal databases and Surveillance, Epidemiology, and End Results (SEER) to identify 200 eligible patients including our four cases. According to Kaplan–Meier survival curve analysis, patients <68 years old, with radical prostatectomy (RP), Gleason score of 7–8, and lower clinical stage had longer overall survival (OS). Moreover, Cox multivariate analysis indicated that race (hazard ratio [HR] = 1.422), surgical approach (HR = 1.654), and Gleason score (HR = 2.162) were independent prognostic factors for OS. Therefore, primary SRCC of the prostate represents a distinct and aggressive subtype of prostate cancer associated with a higher distribution of PD-L1 and TAMs, which warrants further clinical investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunohistochemical analysis of PD-L1 and tumor-infiltrating immune cells expression in the tumor microenvironment of primary signet ring cell carcinoma of the prostate

Fan¹,

Liu²,

Teng³

et al. 2022

Asian Journal of Andrology

View full text Add to dashboard Cite

show abstract

“…Prostatic signet-ring carcinoma is an aggressive and rare type of prostate cancer. It was first reported by Uyama and Moriwaki in 1979 [3][4][5][6][7][8]. Although signet ring carcinoma more commonly occurs in the gastrointestinal tract, mainly the stomach and colon, it has been documented in various organs of the body, such as the breast, bladder and pancreas.…”

Section: Discussionmentioning

confidence: 99%

“…Complete androgen blockade was also reported to be effective [17]. However, poor response to hormonal therapy has been reported, in addition to the probability for the tu-mor to become castration-resistant [4,9]. Full response has been documented with the use of the chemotherapy combination used for colorectal cancer FOLFOX [18].…”

Section: Discussionmentioning

confidence: 99%

Prostatic signet-ring adenocarcinoma: A case report

Khader¹,

Nsour²,

Edwan³

2022

JOMH

View full text Add to dashboard Cite

Background: Prostatic signet-ring adenocarcinoma is a rare histological variant of prostate cancer. The tumor is characterized by an aggressive clinical course. Methods: Herein we present the case of a 78-year-old man with obstructive urinary symptoms and elevated serum prostate specific antigen. Transurethral resection of the prostate was performed. Results: Histologically, a tumor that was mainly composed of signet ring cells was identified. The tumor cells were positive for alcian blue special stain. Another Gleason 4 adenocarcinoma component was identified. The patient received hormonal therapy. A favorable response was documented at 8 months of follow up. Conclusions: Ruling out another primary site of origin, such as the gastrointestinal tract, is mandatory, and a more aggressive management plan should be put in mind.

show abstract

“…It is a dedifferentiated adenocarcinoma, histologically characterized by round-shaped cells, with peripherally placed nuclei and cytoplasmic vacuoles filled with mucin [7,8]. SRCC is usually located in the stomach but can also be found in other tissues like prostate [9], breast [10], testis [11] and ovary [12], bladder [13], lung [14], colon [15], gallbladder [16] and Vater ampulla [17]. To the best of our knowledge only 5 cases of SRCC of the bile ducts are described in literature, all of them referring to extrahepatic bile ducts SRCC [18,19,20,21,22].…”

Section: Discussionmentioning

confidence: 99%

Microangiopathic hemolytic anemia caused by a signet-ring cell carcinoma of the intrahepatic bile duct

Younes

Ponzo

Marzano

2017

Minerva Gastroenterol

View full text Add to dashboard Cite

show abstract

A case with primary signet ring cell adenocarcinoma of the prostate and review of the literature

Cited by 11 publications

References 9 publications

Immunohistochemical analysis of PD-L1 and tumor-infiltrating immune cells expression in the tumor microenvironment of primary signet ring cell carcinoma of the prostate

Immunohistochemical analysis of PD-L1 and tumor-infiltrating immune cells expression in the tumor microenvironment of primary signet ring cell carcinoma of the prostate

Prostatic signet-ring adenocarcinoma: A case report

Microangiopathic hemolytic anemia caused by a signet-ring cell carcinoma of the intrahepatic bile duct

Contact Info

Product

Resources

About